Group One Trading
PHAT icon

Group One Trading’s Phathom Pharmaceuticals PHAT Stock Holding History

Group One Trading’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.77K Buy
+900
New +$10.3K ﹤0.01% 6406
2025
Q4 		– Sell
-1,500
Closed -$17.7K – 8915
2025
Q3 		$17.7K Sell
1,500
-24,600
-94% -$254K ﹤0.01% 6796
2025
Q2 		$250K Buy
26,100
+15,700
+151% +$86.9K ﹤0.01% 4113
2025
Q1 		$65.2K Buy
10,400
+9,800
+1,633% +$59.5K ﹤0.01% 4941
2024
Q4 		$4.87K Sell
600
-23,100
-97% -$286K ﹤0.01% 6421
2024
Q3 		$428K Hold
23,700
– – ﹤0.01% 2972
2024
Q2 		$244K Sell
23,700
-2,400
-9% -$24.7K ﹤0.01% 3233
2024
Q1 		$277K Buy
26,100
+25,000
+2,273% +$212K ﹤0.01% 3281
2023
Q4 		$10K Buy
1,100
+900
+450% +$7.75K ﹤0.01% 6198
2023
Q3 		$2.07K Sell
200
-1,200
-86% -$16.5K ﹤0.01% 7024
2023
Q2 		$20K Buy
+1,400
New +$16.1K ﹤0.01% 5996

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Group One Trading's PHAT Position: Q2 2026 in Review

Group One Trading reduced its Phathom Pharmaceuticals (PHAT) stake by 18% in Q2 2026, selling an estimated $34.9K and leaving 13,881 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #4522.

Group One Trading first reported a position in PHAT in Q4 2023 and has held it in 8 quarters since. The position peaked at $1.72M in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Group One Trading held 13,881 shares of Phathom Pharmaceuticals worth $151K as of Q2 2026.
  • Group One Trading sold 3,058 Phathom Pharmaceuticals shares in Q2 2026, an estimated $34.9K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #4522 holding.
  • Group One Trading first reported a position in Phathom Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
  • Group One Trading's Phathom Pharmaceuticals position peaked at $1.72M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.